Wyeth Pharmaceutical Division Of Wyeth Holdings Corporation, A Subsidiary Of Pfizer Inc.

Wyeth Pharmaceutical Division Of Wyeth Holdings Corporation, A Subsidiary Of Pfizer Inc. Drugs

• Prevnar
  

  ×

  Prevnar

  

  ---

  For intramuscular injection only. Do not inject intravenously.

  The dose is 0.5 mL to be given intramuscularly.

  Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a uniform suspension in the vaccine container. The vaccine should not be used if it cannot be resuspended.

  After shaking, the vaccine is a homogeneous, white suspension.

  The vaccine is not to be mixed with other vaccines/products in the same syringe.

  Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration (see DESCRIPTION). This product should not be used if particulate matter or discoloration is found.

  The vaccine should be injected intramuscularly. The preferred sites are the anterolateral aspect of the thigh in infants or the deltoid muscle of the upper arm in toddlers and young children. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel. Before injection, the skin at the injection site should be cleansed and prepared with a suitable germicide. After insertion of the needle, aspirate and wait to see if any blood appears in the syringe, which will help avoid inadvertent injection into a blood vessel. If blood appears, withdraw the needle and prepare for a new injection at another site.

  Vaccine Schedule

  For infants, the immunization series of Prevnar® consists of three doses of 0.5 mL each, at approximately 2-month intervals, followed by a fourth dose of 0.5 mL at 12-15 months of age. The customary age for the first dose is 2 months of age, but it can be given as young as 6 weeks of age. The recommended dosing interval is 4 to 8 weeks. The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.

  Vaccination schedule for infants and toddlers Dose: Dose 1*† Dose 2† Dose 3† Dose 4‡ Age at Dose: 2 months 4 months 6 months 12-15 months * Dose 1 may be given as early as 6 weeks of age.† The recommended dosing interval is 4 to 8 weeks. ‡ The fourth dose should be administered at approximately 12-15 months of age, and at least 2 months after the third dose.

  Previously Unvaccinated Older Infants and Children

  For previously unvaccinated older infants and children, who are beyond the age of the routine infant schedule, the following schedule applies:31

  Vaccine schedule for previously unvaccinated children ≥7 months of age Age at First Dose Total Number of 0.5 mL Doses 7-11 months of age 3* 12-23 months of age 2† ≥24 months through 9 years of age 1 * 2 doses at least 4 weeks apart; third dose after the one-year birthday, separated from the second dose by at least 2 months. † 2 doses at least 2 months apart.

  (See CLINICAL PHARMACOLOGY section for the limited available immunogenicity data and ADVERSE REACTIONS section for limited safety data corresponding to the previously noted vaccination schedule for older children).

  Safety and immunogenicity data are either limited or not available for children in specific high risk groups for invasive pneumococcal disease (eg, persons with sickle cell disease, asplenia, HIV-infected).

  Close
  More Info
• Fibercon
  

  ×

  Fibercon

  

  ---

  Directions

  take each dose of this product with at least 8 ounces (a full glass) of water or other fluid. Taking this product without enough liquid may cause choking. See choking warning. FiberCon works naturally so continued use for one to three days is normally required to provide full benefit. Dosage may vary according to diet, exercise, previous laxative use or severity of constipation. age recommended dose daily maximum adults and children 12 years of age and over 2 caplets once a day up to 4 times a day children under 12 years consult a physician  

  Close
  More Info
• Prevnar 13
  

  ×

  Prevnar 13

  

  ---

  2.1 Preparation for Administration

  Since this product is a suspension containing an adjuvant, shake vigorously immediately prior to use to obtain a homogenous, white suspension in the vaccine container. Do not use the vaccine if it cannot be resuspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration [see Description (11)]. This product should not be used if particulate matter or discoloration is found.

  Do not mix Prevnar 13 with other vaccines/products in the same syringe.

  2.2 Administration Information

  For intramuscular injection only.

  Each 0.5 mL dose is to be injected intramuscularly using a sterile needle attached to the supplied prefilled syringe. The preferred sites for injection are the anterolateral aspect of the thigh in infants and the deltoid muscle of the upper arm in toddlers, children and adults. The vaccine should not be injected in the gluteal area or areas where there may be a major nerve trunk and/or blood vessel.

  2.3 Vaccination Schedule for Infants and Toddlers

  Prevnar 13 is to be administered as a four-dose series at 2, 4, 6, and 12–15 months of age.

  Table 1: Vaccination Schedule for Infants and Toddlers Dose Dose 1*,† Dose 2† Dose 3† Dose 4‡ * Dose 1 may be given as early as 6 weeks of age. † The recommended dosing interval is 4 to 8 weeks. ‡ The fourth dose should be administered at approximately 12–15 months of age, and at least 2 months after the third dose. Age at Dose 2 months 4 months 6 months 12–15 months

  2.4 Vaccination Schedule for Unvaccinated Children 7 Months Through 5 Years of Age

  For children 7 months through 5 years of age who have not received Prevnar® or Prevnar 13, the catch-up schedule in Table 2 applies:

  Table 2: Vaccination Schedule for Unvaccinated Children 7 Months of Age Through 5 Years of Age Age at First Dose Total Number of 0.5 mL Doses * The first 2 doses at least 4 weeks apart; third dose after the one-year birthday, separated from the second dose by at least 2 months. † Two doses at least 2 months apart. 7–11 months of age 3* 12–23 months of age 2† 24 months through 5 years of age (prior to the 6th birthday) 1

  The immune responses induced by this catch-up schedule may result in lower antibody concentrations for some serotypes, compared to antibody concentrations following 4 doses of Prevnar 13 (given at 2, 4, 6, and 12–15 months). In children 24 months through 5 years of age, lower antibody concentrations were observed for some serotypes, compared to antibody concentrations following 3 doses of Prevnar 13 (given at 2, 4, and 6 months).

  2.5 Vaccination Schedule for Children Previously Vaccinated With Prevnar Pneumococcal 7-valent Conjugate Vaccine (Diphtheria CRM197 Protein)

  Children 15 months through 5 years of age who are considered completely immunized with Prevnar may receive one dose of Prevnar 13 to elicit immune responses to the 6 additional serotypes. This catch-up (supplemental) dose of Prevnar 13 should be administered with an interval of at least 8 weeks after the final dose of Prevnar. The immune responses induced by this Prevnar 13 schedule may result in lower antibody concentrations for the 6 additional serotypes (types 1, 3, 5, 6A, 7F, and 19A), compared to antibody concentrations following 4 doses of Prevnar 13 (given at 2, 4, 6, and 12–15 months).

  2.6 Vaccination Schedule for Children 6 Years Through 17 Years of Age

  In children 6 years through 17 years of age, Prevnar 13 is administered as single dose. If Prevnar was previously administered, then at least 8 weeks should elapse before receiving Prevnar 13.

  2.7 Vaccination Schedule for Adults 50 years of Age and Older

  Prevnar 13 is administered as a single dose.

  Close
  More Info
• Acetaminophen Pain Reli...
  

  ×

  Acetaminophen Pain Reliever Fever Reducer

  

  ---

  For intramuscular use only.

  2.1 Dose and Schedule

  Administer Trumenba as a three dose series (0.5 mL each) according to a 0-, 2-, and 6-month schedule.

  2.2 Administration

  Shake syringe vigorously to ensure that a homogenous white suspension of Trumenba is obtained. Do not use the vaccine if it cannot be re-suspended. Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit. Do not use if particulate matter or discoloration is found.

  Inject each 0.5 mL dose intramuscularly, using a sterile needle attached to the supplied prefilled syringe. The preferred site for injection is the deltoid muscle of the upper arm. Do not mix Trumenba with any other vaccine in the same syringe.

  2.3 Use of Trumenba with other Meningococcal Group B Vaccines

  Sufficient data are not available on the safety and effectiveness of using Trumenba and other meningococcal group B vaccines interchangeably to complete the vaccination series.

  Close
  More Info